ADVERTISEMENT

Comments?
Help us improve Portfolio Grader.


Comments?
Help us improve Portfolio Grader.


Blue Chip Growth

Stock Report: "Synergy Pharmaceuticals, Inc." (SGYP) Report Updated: Aug 22, 2016 | Print This Page

Get more stock ratings by Louis Navellier

"Synergy Pharmaceuticals, Inc." (SGYP)

Rating: Sell Volatility: Moderate
Total Grade: D Industry: Biotechnology
Competitors: CYTK,MNOV,EXEL,DMPI

Stock Analysis

Rating: Monthly View

A
B
C
D
F
August September October November December January February March April May June July

Rating: Weekly View

This Week: D down no change
Last Week: D same upgrade
Two Weeks Ago: F up downgrade
service keys

"Synergy Pharmaceuticals, Inc."© quotemedia

Company Profile

Synergy Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development of drugs to treat gastrointestinal (GI) disorders and diseases. Its lead product candidate is plecanatide, a guanylyl cyclase C receptor agonist that is in Phase III clinical trials to treat chronic idiopathic constipation GI disorders; and for the treatment of constipation-predominant irritable bowel syndrome GI disorders. The company is also developing SP-333, which is in Phase II clinical trials to treat opioid induced constipation, as well as in Phase Ib clinical trials to treat ulcerative colitis. Synergy Pharmaceuticals Inc. is headquartered in New York, New York.